Overview

Ameliorating Contrast Induced Nephropathy After Coronary Angiography

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:
0

Participant gender:
All

Summary

Given the limited understanding of the impact of statin and N-acetyl cysteine use before angiography in preventing contrast-induced nephropathy (CIN), the objective of this study is to evaluate the effectiveness of atorvastatin in preventing CIN among patients undergoing coronary angiography.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ain Shams University

Treatments:

Acetylcysteine
Atorvastatin
N-monoacetylcystine

Criteria

Inclusion Criteria:

- Undergoing elective Coronary angiography who will receive coronary angiography
contrast media.

- Must have at least two consecutive serum creatinine measurements (Before and after
Contrast exposure)

Exclusion Criteria:

- Pregnant or lactating women

- Patients with Serum creatinine conc of >2.1 mg/Dl

- Patients undergoing emergency primary percutaneous coronary intervention for
ST-segment elevation myocardial infarction.

- Prior exposure to contrast media within 7 days

- Contraindication for a high-dose statin, N-acetyl Cysteine prescription